



Rescission of NC State Health Director's Standing Order Authorizing Intravenous Administration of  
Bamlanivimab/ Etesevimab Monoclonal Antibodies

I hereby rescind the standing order authorizing Intravenous Administration of Bamlanivimab/ Etesevimab Monoclonal Antibodies that was issued on January 5<sup>th</sup>, 2022 due to the high prevalence of the Omicron variant of SARS-CoV-2 virus in North Carolina for which Bamlanivimab/ Etesevimab is not an effective treatment.

The rescission of this standing order shall not impact any actions taken in reliance on this standing order prior to the date of rescission.

Handwritten signature of Elizabeth Cuervo Tilson in black ink.

Approved by: \_\_\_\_\_

Elizabeth Cuervo Tilson, MD, MPH  
NPI: 1760540421

Date Signed: 1-24-22\_\_\_\_\_